Supporting balance. Protecting what matters.
*Not available in the US
CytoSorb® uses polymer-bead adsorption technology to provide an extracorporeal blood-purification solution intended for use in critical-care conditions.
It is designed to reduce certain substances that, at excessive levels, may be harmful to the body.
Published clinical experience has reported favorable safety data and associations with improvements in hemodynamic stability, tissue perfusion, and organ support when used as part of multimodal treatment approaches.
Extensive clinical experience
With more than 300,000 hemoadsorption treatments performed worldwide over the past ten years, CytoSorb® technology has been extensively used in clinical practice and continuously monitored for safety and performance.
Over 1,100 scientific contributions
CytoSorbents’ hemoadsorption technology is supported by a large and growing body of peer-reviewed literature and clinical evidence.
Clinical experience across multiple indications
Research and clinical use of CytoSorbents’ hemoadsorption therapies have been reported in cardiovascular, renal, hepatic, and critical-care settings.
How CytoSorb Works – Mode of Action in Brief
Healthy balance
Normal body function depends on maintaining physiological balance.
However, several factors may lead to potentially harmful imbalances:
- Uncontrolled overproduction of mediators following triggers such as infection
- Excessive release of substances due to significant cellular damage
- Insufficient removal because of organ dysfunction
- Presence of externally administered substances
- A combination of these factors
CytoSorb® — Designed to Support Physiological Balance:
CytoSorb® is intended for the adsorptive removal of selected substances from blood or plasma that, at elevated levels, may be harmful to the body. Approved indications for use are:
- Cytokine adsorption in intensive-care and cardiac-surgery settings
- Adsorption of bilirubin in liver dysfunction
- Adsorption of myoglobin in rhabdomyolysis
- Intra-operative adsorption of selected antithrombotic agents during cardiopulmonary bypass (CPB)
-
Healthy balance
Normal body function depends on maintaining physiological balance.
-
However, several factors may lead to potentially harmful imbalances:
- Uncontrolled overproduction of mediators following triggers such as infection
- Excessive release of substances due to significant cellular damage
- Insufficient removal because of organ dysfunction
- Presence of externally administered substances
- A combination of these factors
-
CytoSorb® — Designed to Support Physiological Balance:
CytoSorb® is intended for the adsorptive removal of selected substances from blood or plasma that, at elevated levels, may be harmful to the body. Approved indications for use are:
- Cytokine adsorption in intensive-care and cardiac-surgery settings
- Adsorption of bilirubin in liver dysfunction
- Adsorption of myoglobin in rhabdomyolysis
- Intra-operative adsorption of selected antithrombotic agents during cardiopulmonary bypass (CPB)
Hemoadsorption Technology Based on Polymer Bead Design
- CytoSorb cartridges are packed with highly porous polymer beads engineered for selective adsorption.
- As blood passes through, the beads bind hydrophobic and protein-bound molecules within a vast pore network, while their biocompatible surface minimizes interaction with blood components.
- The concentration-dependent adsorption mechanism favors removal of molecules at high concentrations, supporting preservation of essential mediators at physiological levels.
Distinctive adsorption criteria for safe and effective rebalancing
Utilization of hydrophobic attraction to surface
Size selection :< approx. 60 kDa
Concentration-dependent removal
-
Utilization of hydrophobic attraction to surface
-
Size selection :< approx. 60 kDa
-
Concentration-dependent removal
Use of CytoSorb in Therapeutic Areas
CytoSorb can be integrated into various therapeutic areas for extracorporeal blood purification in intensive-care and surgical applications.
-
Critical Care
Intended to adsorb selected cytokines, inflammatory mediators, and toxins from whole blood to support management of systemic inflammatory responses.
-
Cardiovascular Care
May be used in patients at risk of hyperinflammatory responses or intra-operatively during CPB to adsorb certain antithrombotic agents such as ticagrelor or rivaroxaban.
-
Liver Care
Intended to remove selected cytokines, bilirubin, and other hydrophobic metabolites to support management of hyperbilirubinemia and systemic inflammation.
-
Kidney Care
Intended to adsorb selected cytokines and myoglobin, either as a stand-alone modality or combined with renal-replacement therapies as part of a multimodal approach.
Additional Information
- Jansen et al., Crit Care 2023; 27(1):117
- Diab et al., Circ 2022; 145(13):959-968
- Scharf et al., Sci Rep 2021; 11(1);10190
- Albrecht et al., Blood Purif 2024; 53(2):88-95
- Hassan et al., JTCVS Open 2023; 15:190-196
- Chen J et al, Regenerative Biomaterials 2017; 4(1):31-37
- Waalders et al., Crit Care Med 2024; 52(4):e152-e153
- Bernardi et al., Crit Care 2016; 20(1):96
- Poli et al., Crit Care 2019; 23:108
- Gleason et al., Sem Thorac Cardiovasc Surg 2019; 31(4):783-793
- David et al., J Int Care 2017; 5:12
- Kogelmann et al., J Clin Med 2024; 13(1):294
- Soltesz et al., J Clin Med 2022; 11(12):6517
- Rugg C et al., Biomedicines 2020; 8(12):539
- Szigetvary et al., Biomed 2023; 11811):3068
- Riva et al., J Artif Orgs 2023; epub
- Grafe et al., Ren Fail 2023; 45(2):2259231
- Hassan et al., Ann Thor Cardiovasc Surg 2022; 28(3):186-192
- Hassan et al., Ann Thorac Surg 2019; 108(1):45-51
CytoSorb 300 IFU Indications (03/2023):
CytoSorb is indicated for use in conditions where elevated levels of cytokines and/or bilirubin and/or myoglobin exist. CytoSorb is indicated for use intraoperatively during cardio-pulmonary bypass surgery for the removal of P2Y12-Inhibitor Ticagrelor and/or Factor Xa-Inhibitor Rivaroxaban. Results from current studies suggest that CytoSorb may be administered for up to 7 consecutive days. Maximum Treatment Time per Device: 24 Hour.
Voices around the world
